Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
br Introduction Major depressive disorder MDD is a disease
2022-04-08

Introduction Major depressive disorder (MDD) is a disease with poorly recognized etiology. Currently used antidepressant drugs, which mainly affect synaptic neurotransmitter levels, show full clinical efficacy in only one third of patients (Rush, 2007). Thus it is now generally accepted that the
-
Acknowledgments br Introduction Type diabetes mellitus T DM
2022-04-08

Acknowledgments Introduction Type 2 diabetes mellitus (T2DM) is caused by relative insulin deficiency or insulin resistance in peripheral tissues. The clinical management of T2DM is achieved by controlling blood glucose levels. Current therapies available for treatment of T2DM include biguanides
-
Decreases in LS mean h WMG versus placebo
2022-04-08

Decreases in LS mean 24-h WMG versus placebo were observed with both the 10mg q.d. a.m. (−18.8mg/dL) and 6mg q.d. p.m. (−25.0mg/dL) MK-3577 ‘partial blockade’ regimens, but was not assessed for the 25mg b.i.d regimen. Decreases in FPG versus placebo were observed for both the 10mg q.d. a.m. (−7.2mg/
-
br Acknowledgements This work was
2022-04-08

Acknowledgements This work was supported by a fellowship to C.H. under the ‘100 Foreign Expert’ scheme of the Shanxi province government(R100456). Conflict of interest: Dr. Holscher is a named inventor on a patent submitted by Lancaster University on the use of dual GLP-1/GIP analogues in neurode
-
br Acknowledgments The authors gratefully acknowledge the
2022-04-07

Acknowledgments The authors gratefully acknowledge the support provide by National Natural Science Foundation of China (Number 31301415). Introduction β-Galactosidases (EC 3.2.1.23), frequently known as lactases, are widely used in lactose hydrolysis. This disaccharide is present in mammalian
-
We next determined the selectivity profile
2022-04-07

We next determined the selectivity profile of the most potent GPR40 agonists (4k–n) against other free fatty IFN-alpha 1, human recombinant protein receptors (FFA3/GPR41, FFA2/GPR43 and FFA4/GPR120). FFA2 and FFA3 agonists have a preference in binding short-chain fatty acids while FFA1 and FFA4 hav
-
The physicochemical properties of the
2022-04-07

The physicochemical properties of the prodrugs provided important clues for understanding a broad range of inhibitory activities in the cell assays (Table 2). Some physicochemical properties are useful in predicting drug absorption. Considering Lipinski’s rules and the polar surface area (PSA),l-ala
-
The ability of the vasculature to determine the nature
2022-04-07

The ability of the vasculature to determine the nature and magnitude of a stimulus is essential for the appropriate and proportionate response. The vascular response to injury include rapid changes to blood flow to reduce the loss of blood, followed by increased contact with the sub-endothelial laye
-
The effect of combined A and PD
2022-04-07

The effect of combined A-192621 and PD 155080 treatment on the Tolcapone during endotoxin infusion is quite different compared to either drug used alone (Wanecek et al., 1999). After administration of both antagonists in combination, cardiac index increased to baseline values within 30 min, and was
-
To identify genes with significant expression differences we
2022-04-07

To identify genes with significant h106 synthesis differences, we performed differential gene expression analysis between the two individuals with TRRAP variants (combined as biological replicates) and two unaffected controls. Gene ontology (GO) enrichment analysis of these genes with the GOrilla w
-
br Experimental br Results br
2022-04-07

Experimental Results Discussion In this study, we performed molecular docking analysis and in vitro studies to determine whether genistein binds to HIF-1α in BC ODM-201 and identify the residues involved in this interaction. We found that some functional groups (residues) mimic the binding
-
The stress of accelerated lactate
2022-04-06

The stress of accelerated lactate production in cancer SIS3 australia is moderated by the overexpression of lactate transporters – symporters for lactate anions and protons called monocarboxylate transporters (MCTs) – that are capable of bidirectional transport depending on the environmental and/or
-
To date no studies have demonstrated any effect of obesity
2022-04-06

To date, no studies have demonstrated any effect of obesity or inflammation on GPR109A expression in adipose tissue. Our findings demonstrate that HFD-induced obesity decreases adipose tissue GPR109A gene expression. Contradictory to our findings in adipose tissue in vivo, Digby et al. report that e
-
The mechanisms of action of MMF
2022-04-06

The mechanisms of action of MMF and DMF are not well understood, but a growing body of evidence has demonstrated that DMF may act on both the neurodegenerative and inflammatory response of MS patients. The majority of the data related to the mechanism of action of DMF/MMF demonstrates the associatio
-
br Materials and methods br Results and
2022-04-06

Materials and methods Results and discussion We recently found that the GlyT1 N-terminal and C-terminal sequences could be modified by phophorylation, or partially lost under pathological conditions by calcium-dependent proteolysis (Baliova and Jursky, 2005, Baliova and Jursky, 2010). While re
16436 records 483/1096 page Previous Next First page 上5页 481482483484485 下5页 Last page